Sangamo Therapeutics, Inc (SGMOQ) stock
SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q1 năm tài chính 2026, quý kết thúc ngày Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 4/30
$0.10−0.01 (-8.17%)
Close on Oct 19, 2026Market cap $39.43MP/E –Yield –
Sangamo Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Sangamo Therapeutics's operating cash flow for the twelve months ending Mar 31, 2026 was -$90.34M. For fiscal 2025 it was -$97.21M. The highest annual figure on record is $169.88M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$97.21M | – |
| FY2024 | Dec 31, 2024 | -$67.14M | – |
| FY2023 | Dec 31, 2023 | -$224.84M | – |
| FY2022 | Dec 31, 2022 | -$223.63M | – |
| FY2021 | Dec 31, 2021 | -$233.25M | -237.3% |
| FY2020 | Dec 31, 2020 | $169.88M | – |
| FY2019 | Dec 31, 2019 | -$144.40M | -495.1% |
| FY2018 | Dec 31, 2018 | $36.55M | +227.0% |
| FY2017 | Dec 31, 2017 | $11.18M | – |
| FY2016 | Dec 31, 2016 | -$65.88M | – |
| FY2015 | Dec 31, 2015 | -$33.72M | – |
| FY2014 | Dec 31, 2014 | -$5.68M | – |
| FY2013 | Dec 31, 2013 | -$19.48M | – |
| FY2012 | Dec 31, 2012 | -$8.08M | – |
| FY2011 | Dec 31, 2011 | -$25.90M | – |
| FY2010 | Dec 31, 2010 | -$23.93M | – |
| FY2009 | Dec 31, 2009 | -$6.14M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -$19.28M | – |
| Q4 FY2025 | Dec 31, 2025 | -$24.40M | – |
| Q3 FY2025 | Sep 30, 2025 | -$28.50M | -342.4% |
| Q2 FY2025 | Jun 30, 2025 | -$18.16M | – |
| Q1 FY2025 | Mar 31, 2025 | -$26.15M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.35M | – |
| Q3 FY2024 | Sep 30, 2024 | $11.76M | – |
| Q2 FY2024 | Jun 30, 2024 | -$26.88M | – |
| Q1 FY2024 | Mar 31, 2024 | -$48.66M | – |
| Q4 FY2023 | Dec 31, 2023 | -$50.54M | – |
| Q3 FY2023 | Sep 30, 2023 | -$47.29M | – |
| Q2 FY2023 | Jun 30, 2023 | -$60.71M | – |
| Q1 FY2023 | Mar 31, 2023 | -$66.30M | – |
| Q4 FY2022 | Dec 31, 2022 | -$57.05M | – |
| Q3 FY2022 | Sep 30, 2022 | -$53.62M | – |
| Q2 FY2022 | Jun 30, 2022 | -$53.99M | – |
| Q1 FY2022 | Mar 31, 2022 | -$58.98M | – |
| Q4 FY2021 | Dec 31, 2021 | -$52.71M | – |
| Q3 FY2021 | Sep 30, 2021 | -$59.42M | -279.7% |
| Q2 FY2021 | Jun 30, 2021 | -$52.57M | -132.9% |
| Q1 FY2021 | Mar 31, 2021 | -$68.55M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.30M | – |
| Q3 FY2020 | Sep 30, 2020 | $33.07M | – |
| Q2 FY2020 | Jun 30, 2020 | $159.99M | – |
| Q1 FY2020 | Mar 31, 2020 | -$18.89M | – |
| Q4 FY2019 | Dec 31, 2019 | -$20.82M | – |
| Q3 FY2019 | Sep 30, 2019 | -$38.87M | – |
| Q2 FY2019 | Jun 30, 2019 | -$39.59M | -132.3% |
| Q1 FY2019 | Mar 31, 2019 | -$45.12M | – |
| Q4 FY2018 | Dec 31, 2018 | -$40.16M | – |
| Q3 FY2018 | Sep 30, 2018 | -$27.60M | – |
| Q2 FY2018 | Jun 30, 2018 | $122.44M | +115.6% |
| Q1 FY2018 | Mar 31, 2018 | -$18.13M | – |
| Q4 FY2017 | Dec 31, 2017 | -$16.84M | – |
| Q3 FY2017 | Sep 30, 2017 | -$15.69M | – |
| Q2 FY2017 | Jun 30, 2017 | $56.79M | – |
| Q1 FY2017 | Mar 31, 2017 | -$13.08M | – |
| Q4 FY2016 | Dec 31, 2016 | -$11.77M | – |
| Q3 FY2016 | Sep 30, 2016 | -$17.58M | – |
| Q2 FY2016 | Jun 30, 2016 | -$16.18M | – |
See a number that looks wrong?